AI Analysis
AI-generated analysis. Always verify with the original filing.
Net Income was -$16.2M (23.1%)
Key Takeaways
1Net loss improved 23.1% to -$16.2M from -$21.1M as operating expenses declined amid clinical trial advancements.
2R&D expenses include capitalized supplies for future use and third-party clinical trial costs expensed as performed.
3Future G&A expenses expected to rise with business growth, public company costs, and infrastructure expansion.
4Company plans preclinical studies post-FDA meeting to advance toward future toxicology studies.